Cambridge, United Kingdom
Qureight is an innovative end-to-end imaging CRO that aims to transform the clinical trials landscape by accelerating processes for the biopharmaceutical industry. Their cutting-edge AI-powered platform specializes in the analysis and curation of clinical imaging and healthcare data specifically for patients suffering from lung and heart diseases. By offering enterprise-grade imaging and precision endpoints, Qureight enables faster market readiness for treatments.
Founded in 2018, Qureight operates out of Cambridge and London, UK, and focuses on therapeutic areas like Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension. The startup recently secured an $8.50M Series A investment, supported by a diverse group of investors including Playfair Capital, Cambridge Angels, and XTX Ventures. This investment underscores the confidence and potential seen in Qureight's mission to streamline clinical trial processes through advanced technology.
